Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

NCT00520533 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Closed prematurely due to toxicity

Conditions

Renal Cell Carcinoma (RCC)

Interventions

BIOLOGICAL: Chimeric monoclonal antibody cG250
DRUG: Sunitinib malate

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]